Search

Sarepta Therapeutics to Announce Second Quarter 2022 Financial Results and Recent Corporate Developments on August 2, 2022
Community Bulletin: Intent to Submit an Accelerated Approval Biologics License Application for SRP-9001
Sarepta Therapeutics Announces Intent to Submit an Accelerated Approval Biologics License Application for its Gene Therapy SRP-9001 to Treat Duchenne Muscular Dystrophy
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces Second Quarter 2022 Financial Results and Recent Corporate Developments
Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Signs Agreement with Hansa Biopharma for Imlifidase
Rare Lessons
Sarepta Therapeutics Launches “Rare Lessons” Program to Promote Greater Diversity and Inclusion in the Classroom and Support Awareness of Rare Diseases